Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;14(1):375-90.
doi: 10.1208/s12249-012-9905-1. Epub 2013 Jan 24.

Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications

Affiliations

Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications

S C Nichols et al. AAPS PharmSciTech. 2013 Mar.

Abstract

The multi-stage cascade impactor (CI) is widely used to determine aerodynamic particle size distributions (APSDs) of orally inhaled products. Its size-fractionating capability depends primarily on the size of nozzles of each stage. Good Cascade Impactor Practice (GCIP) requires that these critical dimensions are linked to the accuracy of the APSD measurement based on the aerodynamic diameter size scale. Effective diameter (Deff) is the critical dimension describing any nozzle array, as it is directly related to stage cut-point size (d50). d50 can in turn be determined by calibration using particles of known aerodynamic diameter, providing traceability to the international length standard. Movements in Deff within manufacturer tolerances for compendial CIs result in the worst case in shifts in d50 of <±10%. Stage mensuration therefore provides satisfactory control of measurement accuracy. The accurate relationship of Deff to d50 requires the CI system to be leak-free, which can be checked by sealing the apparatus at the entry to the induction port and isolating it from the vacuum source and measuring the rate of pressure rise before each use. Mensuration takes place on an infrequent basis compared with the typical interval between individual APSD determinations. Measurement of stage flow resistance (pressure drop; ΔPstage) could enable the user to know that the CI stages are fit for use before every APSD measurement, by yielding an accurate measure of Deff. However, more data are needed to assess the effects of wear and blockage before this approach can be advocated as part of GCIP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The relationships between specifications for critical dimensions associated with cascade impactors
Fig. 2
Fig. 2
Strategy for implementing CI System leak testing as part of “in-use” GCIP
Fig. 3
Fig. 3
Cross-section through an ideal single-stage impactor showing the motion of particles of different sizes; W is the nozzle exit diameter (a critical dimension for verification) and S is the nozzle exit to collection surface distance (relatively insensitive to variability in a well-designed system)
Fig. 4
Fig. 4
The relationship of effective diameter D eff from annual mensuration (one data point per mensuration) to predicted D eff from flow resistance measurements (stage pressure drop) for stage 4 (nominal D eff = 1.207 mm) for six NGIs; the gray square represents the range for D eff allowed by the manufacturer tolerance for this stage (±0.01 mm) in Table V
Fig. 5
Fig. 5
Relationship between optically mensurated area-mean diameter and flow resistance-predicted area-mean diameter (D*) for stage 6 of an NGI, intentionally blocking two, four, six, and eight out of the 396-nozzle array for this stage; the fully open condition is also shown at far left of the figure

Similar articles

Cited by

References

    1. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, et al. Considerations for the development and practice of cascade impaction testing including a mass balance failure investigation tree. J Aerosol Med. 2003;16(3):235–247. doi: 10.1089/089426803769017604. - DOI - PubMed
    1. Mitchell J, Newman S, Chan H-K. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech. 2007;8(4). doi:10.1208/pt0804110. Article 110. - PMC - PubMed
    1. Newman SP, Chan H-K. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med. 2008;21(1):1–8. - PubMed
    1. European Directorate for Quality in Medicines and HealthCare (EDQM). Monograph 2.9.18: European Pharmacopeia, Preparations for inhalation: aerodynamic assessment of fine particles, Council of Europe, 67075 Strasbourg, France, 2012; Ph.Eur.7.5 [USB 7th ed. (7.52012)].
    1. United States Pharmacopeial Convention. Chapter 601: Aerosols, Nasal Sprays, Metered-Dose Inhalers and Dry Powder Inhalers. Rockville, MD, USA, 2012; USP 35-NF 30.

LinkOut - more resources